Erik Swain

Proton beam therapy, a radiation treatment for cancer, may be effective as a treatment for refractory ventricular tachycardia, according to results of a first-in-human study presented at Heart Rhythm 2026.

A novel bipolar conduction system pacing implantable cardioverter defibrillator lead demonstrated short-term safety and efficacy in a pivotal trial, researchers reported at Heart Rhythm 2026.

A novel leadless pacemaker designed for left bundle branch area pacing conferred successful pacing parameters at 1 month, but dislodgement issues have led to a redesign effort, researchers reported at Heart Rhythm 2026.

In patients admitted to the hospital with worsening HF, an early discharge strategy involving treatment at home with subcutaneous furosemide via a

In the first trial of microRNA inhibition to treat heart failure, a novel agent did not reduce left ventricular end-systolic volume index at 6 months compared with placebo in patients with HF and recent MI, researchers reported.

In patients with stable coronary artery disease, colchicine 0.5 mg per day did not impact low-attenuation plaque volume but did improve other plaque metrics, according to the results of the EKSTROM study. For the prospective, randomized, double-blind, placebo-controlled trial, Matthew J. Budoff, MD, FACC, FAHA, investigator at The Lundquist Institute for Biomedical Innovation, and colleagues

Kwame Osei, MD, one of the first researchers to document ethnic disparities in diabetes and glucose regulation, recently died at age 75 years.Osei, a Healio

NEW ORLEANS — More than one-quarter of patients with resistant hypertension had hypercortisolism, suggesting opportunities for screening, researchers reported at the American College of Cardiology Scientific Session.

In patients with advanced heart failure, left ventricular assist device implantation was linked to better 2-year survival than heart transplantation

In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab reduced risk for major adverse CV events compared with placebo, according to new data from the VESALIUS-CV trial. As Healio previously reported, in the main results of VESALIUS-CV, the PCSK9 inhibitor evolocumab (Repatha, Amgen) lowered risk for major adverse CV events by